Delivery Outcomes and Postpartum Readmissions Associated with Ehlers–Danlos Syndrome

Abstract

Objective Given that updated estimates of Ehlers–Danlos syndrome and risks for obstetric complications including postpartum readmission may be of public health significance, we sought to analyze associated obstetric trends and outcomes in a nationally representative population.

Study Design The 2016 to 2020 Nationwide Readmissions Database was used for this retrospective cohort study. Delivery hospitalizations to women aged 15 to 54 with and without Ehlers–Danlos syndrome were identified. Temporal trends in Ehlers–Danlos syndrome diagnoses during delivery hospitalizations were analyzed using joinpoint regression to estimate the average annual percent change with 95% confidence intervals (CIs). To determine whether adverse obstetric outcomes during the delivery were associated with Ehlers–Danlos syndrome, unadjusted and adjusted logistic regression models were fit with unadjusted (odds ratio [OR]) and adjusted ORs with 95% CIs as measures of association. In addition to analyzing adverse delivery outcomes, risk for 60-day postpartum readmission was analyzed.

Results An estimated 18,214,542 delivery hospitalizations were included of which 7,378 (4.1 per 10,000) had an associated diagnosis of Ehlers–Danlos syndrome. Ehlers–Danlos syndrome diagnosis increased from 2.7 to 5.2 per 10,000 delivery hospitalization from 2016 to 2020 (average annual percent change increase of 16.1%, 95% CI: 9.4%, 23.1%). Ehlers–Danlos syndrome was associated with increased odds of nontransfusion severe maternal morbidity (OR: 1.84, 95% CI: 1.38, 2.45), cervical insufficiency (OR: 2.14, 95% CI: 1.46, 3.13), postpartum hemorrhage (OR: 1.41, 95% CI: 1.17, 1.68), cesarean delivery (OR: 1.26, 95% CI: 1.17, 1.36), and preterm delivery (OR: 1.35, 95% CI: 1.16, 1.56). Estimates for transfusion, placental abruption, and placenta previa did not differ significantly. Risk for 60-day postpartum readmission was 3.0% among deliveries with Ehlers–Danlos (OR: 1.76, 95% CI: 1.37, 2.25).

Conclusion Ehlers–Danlos syndrome diagnoses approximately doubled over the 5-year study period and was associated with a range of adverse obstetric outcomes and complications during delivery hospitalizations as well as risk for postpartum readmission.

Key Points

• Ehlers–Danlos syndrome diagnoses approximately doubled over the 5-year study period.

• Ehlers–Danlos was associated with a range of adverse obstetric outcomes.

• Ehlers–Danlos was associated with increased readmission risk.

Keywords

Ehlers–Danlos syndrome - maternal safety - maternal outcomes - severe maternal morbidity

Publication History

Received: 11 August 2023

Accepted: 27 September 2023

Accepted Manuscript online:
04 October 2023

Article published online:
08 November 2023

• References

• 1 Malfait F, Francomano C, Byers P. et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet 2017; 175 (01) 8-26
• 2 Dutta I, Wilson H, Oteri O. Pregnancy and delivery in Ehlers-Danlos syndrome (hypermobility type): review of the literature. Obstet Gynecol Int 2011; 2011: 306413
• 3 Alrifai N, Alhuneafat L, Jabri A. et al. Pregnancy and fetal outcomes in patients with Ehlers-Danlos syndrome: a nationally representative analysis. Curr Probl Cardiol 2023; 48 (07) 101634
• 4 Spiegel E, Nicholls-Dempsey L, Czuzoj-Shulman N, Abenhaim HA. Pregnancy outcomes in women with Ehlers-Danlos syndrome. J Matern Fetal Neonatal Med 2022; 35 (09) 1683-1689
• 5 Hurst BS, Lange SS, Kullstam SM. et al. Obstetric and gynecologic challenges in women with Ehlers-Danlos syndrome. Obstet Gynecol 2014; 123 (03) 506-513
• 6 Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (HCUP). Overview of the Nationwide Readmissions Database. Accessed February 21, 2023 at: https://hcup-us.ahrq.gov/nrdoverview.jsp
• 7 Kurtz SM, Lau EC, Ong KL, Adler EM, Kolisek FR, Manley MT. Which clinical and patient factors influence the national economic burden of hospital readmissions after total joint arthroplasty?. Clin Orthop Relat Res 2017; 475 (12) 2926-2937
• 8 Wen T, Wright JD, Goffman D. et al. Postpartum venous thromboembolism readmissions in the United States. Am J Obstet Gynecol 2018; 219 (04) 401.e1-401.e14
• 9 Wen T, Yu VX, Wright JD. et al. Postpartum length of stay and risk for readmission among women with preeclampsia. J Matern Fetal Neonatal Med 2020; 33 (07) 1086-1094
• 10 Wen T, Overton EE, Sheen JJ. et al. Risk for postpartum readmissions and associated complications based on maternal age. J Matern Fetal Neonatal Med 2021; 34 (09) 1375-1381
• 11 Fein A, Wen T, Wright JD. et al. Postpartum hemorrhage and risk for postpartum readmission. J Matern Fetal Neonatal Med 2021; 34 (02) 187-194
• 12 Healthcare Cost and Utilization Project. Overview of the Nationwide Readmissions Database. Accessed April 1, 2023 at: https://hcup-us.ahrq.gov/nrdoverview.jsp
• 13 Kuklina EV, Whiteman MK, Hillis SD. et al. An enhanced method for identifying obstetric deliveries: implications for estimating maternal morbidity. Matern Child Health J 2008; 12 (04) 469-477
• 14 Clapp MA, James KE, Friedman AM. Identification of delivery encounters using International Classification of Diseases, Tenth Revision, diagnosis and procedure codes. Obstet Gynecol 2020; 136 (04) 765-767
• 15 The Centers for Disease Control and Prevention. Severe maternal morbidity in the United States. Accessed February 20, 2023 at: https://www.cdc.gov/reproductivehealth/maternalinfanthealth/severematernalmorbidity.html
• 16 Main EK, Abreo A, McNulty J. et al. Measuring severe maternal morbidity: validation of potential measures. Am J Obstet Gynecol 2016; 214 (05) 643.e1-643.e10
• 17 Joinpoint Trend Analysis Software. Accessed January 15, 2023 at: https://surveillance.cancer.gov/joinpoint/
• 18 Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 influenza season. MMWR Recomm Rep 2018; 67 (03) 1-20
• 19 The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Accessed May 22, 2023 at: https://www.equator-network.org/reporting-guidelines/strobe//